Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
Multiple System Atrophy Clinical Trial Analysis and Therapeutic Assessment of 20+ Companies and MSA Drugs
Los Angeles, USA, Jan. 13, 2021 (GLOBE NEWSWIRE) -- *Multiple System Atrophy **Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade*
*Multiple System Atrophy Clinical Trial Analysis and Therapeutic Assessment of 20+ Companies and MSA Drugs*
*DelveInsight’s *“*Multiple System Atrophy (MSA) Pipeline Analysis, 2020*” highlights the details of the Multiple System Atrophy Pipeline Landscape Scenario, including disease overview, unmet needs, and Multiple System Atrophy therapeutic assessment of the key Multiple System Atrophy pipeline therapies.
*Some of the key features of the** Multiple System Atrophy Pipeline Report*
· *20+* key companies are working to strengthen the Multiple System Atrophy pipeline including the *MODAG GmbH**, Biogen, GE Healthcare* and several others.
· Multiple System Atrophy market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates.
· *25+* Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include: *BIIB101, verdiperstat (AZD3241), **AAV2-GDNF gene therapy*, etc.
· *Collaborations and Deals*
· *Multiple System Atrophy **Pipeline Drug Profiles provided include:*
· Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
· Multiple System Atrophy Pipeline Drugs Phases of development
· Mechanism of Action
· Route of Administration
· Companies involved including originator, licensing companies, developer, investors, and others
· New molecular entity details
· Multiple System Atrophy Drug designations and other special status provided by regulatory authorities
· Multiple System Atrophy Market Drivers and Barriers
*Multiple System Atrophy* is a rare, degenerative neurological disorder affecting the body's involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The Multiple System Atrophy cause is unknown. The vast majority of cases are sporadic.
*Request Multiple System Atrophy Therapeutics Pipeline Assessment Sample Report*
*Prominent companies participating in the Multiple System Atrophy therapeutic development are covered in the pipeline report. *
*Multiple System Atrophy Pipeline Therapeutics*
· *Verdiperstat *by* Biohaven Pharmaceutical Holding Company*
*Verdiperstat *is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of MPO that *Biohaven Pharmaceutical Holding Company *is developing for Multiple System Atrophy treatment. Verdiperstat also has the potential to be developed in a number of other disease indications associated with oxidative stress, inflammation, and neurodegeneration. Verdiperstat has also been known as *BHV-3241 *at *Biohaven*. The drug is currently in the* phase III* stage of development.
To know more about Multiple System Atrophy Drugs, request @ *Multiple System Atrophy Therapeutics Pipeline Assessment Sample Report*
*Scope of **Multiple System Atrophy Pipeline Therapeutics Report *
· *Coverage: *Global
· *Major Players: 20+ Key Multiple System Atrophy Companies *
· *Multiple System Atrophy Prominent Players: *Brain Neurotherapy Bio, Inc., Biogen, Zambon SpA, EmeraMed, GE Healthcare, Biohaven Pharmaceuticals, Inc., H. Lundbeck A/S, MODAG GmbH, Theravance Biopharma, Voyager Therapeutics Inc, United Neuroscience Ltd, Stealth BioTherapeutics, ProMIS Neurosciences Inc, Newron Pharmaceuticals SpA, Neuropore Therapies Inc, Inhibikase Therapeutics Inc, ICB International Inc, Alterity Therapeutics Ltd, and many others.
· *Key Drugs: 30 Drugs*
· *Multiple System Atrophy Pipeline Therapies**: *Verdiperstat, AAV2-GDNF gene therapy, BIIB101, Safinamide Methanesulfonate, DaTSCAN™ Ioflupane (123I) Injection, [F-18]PBR06, Droxidopa, anle138b, ampreloxetine, VY-SMN101, UB 312, SBT 272, TDP-43 protein inhibitors, Safinamide, NPT 200 11, Alpha-synuclein SMART molecule, ATH 434, EGCG, Rifampicin, Tllsh2910, IVig, Intranasal Insulin, CoQ10, Sirolimus, NBMI, PD01A, PD03A, MSC, PBT-434, Exendin-4, and many others.
· *Multiple System Atrophy Drugs Phases:** *
· Multiple System Atrophy Therapies Late-stage (Phase III)
· Multiple System Atrophy Therapies (Phase II)
· Multiple System Atrophy Therapies (Phase I)
· Multiple System Atrophy Therapies Pre-clinical stage candidates
· Inactive candidates
· *Multiple System Atrophy Drug Targets*
· Protease
· Immune System
· Multiple Kinase
· *Mechanism of Action*
· Protease Inhibitor
· Immunomodulatory
· Multiple Kinase Inhibitor
· *Molecule Types: *
· Small molecule
· Stem Cell Therapy
· Gene Therapy
· *Route of Administration:*
· Inhalation
· Intravenous
· Oral
· Subcutaneous
· *Product Types:*
· Mono
· Combination
*Key Questions regarding Current **Multiple System Atrophy Treatment Landscape** and Emerging Therapies Answered in the Pipeline Report *
· What are the current options for Multiple System Atrophy treatment?
· How many companies are developing therapies for the treatment of Multiple System Atrophy?
· How many Multiple System Atrophy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Multiple System Atrophy?
· What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Multiple System Atrophy market?
· Which are the dormant and discontinued products and the reasons for the same?
· What is the unmet need for current therapies for the treatment of Multiple System Atrophy?
· What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Multiple System Atrophy therapies?
· What are the key designations that have been granted for the emerging therapies for Multiple System Atrophy?
· How many patents are granted and pending for the emerging therapies for the treatment of Multiple System Atrophy?
*Multiple System Atrophy Pipeline** Insight Table of Contents *
*1* *Report Introduction*
*2* *Multiple System Atrophy Executive Summary*
*3* *Multiple System Atrophy Overview*
*4* *Multiple System Atrophy - DelveInsight's Analytical Perspective*
*5* *Multiple System Atrophy Pipeline Therapeutics*
*6* *Multiple System Atrophy Late Stage Products (Phase III)*
*6.1* Verdiperstat - Biohaven Pharmaceutical Holding Company
*7* *Multiple System Atrophy Mid Stage Products (Phase-II)*
*7.1* ATH 434: Alterity Therapeutics
*8* *Multiple System Atrophy Early Stage Products (Phase-I)*
*8.1* Affitope PD03: AFFiRiS
*9* *Multiple System Atrophy Pre-clinical Stage Products*
*9.1* ATH 434: Alterity Therapeutics
*10* *Multiple System Atrophy Therapeutics Assessment*
*11* *Multiple System Atrophy Inactive Products*
*12* *Company-University Collaborations (Licensing/Partnering) Analysis*
*13* *Multiple System Atrophy Key Companies*
*14* *Multiple System Atrophy Key Products*
*15* *Multiple System Atrophy Unmet Needs*
*16* *Multiple System Atrophy* *Market Drivers and Barriers*
*17* *Multiple System Atrophy- Future Perspectives and Conclusion*
*18* *Multiple System Atrophy Analyst Views*
*19* *Appendix*
*Browse Detailed TOC, Emerging Drugs and Key Companies @ **Multiple System Atrophy Pipeline Scenario *
*Related Reports *
· *Multiple System Atrophy Market Analysis *
DelveInsight’s Multiple System Atrophy (MSA) Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
· *Multiple System Atrophy Epidemiology Forecast Analysis *
DelveInsight's Multiple System Atrophy (MSA) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Multiple System Atrophy (MSA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
· *Postmenopausal Vaginal Atrophy Market Analysis *
DelveInsight's Postmenopausal Vaginal Atrophy - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
· *Postmenopausal Vaginal Atrophy Pipeline Analysis *
Postmenopausal Vaginal Atrophy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postmenopausal Vaginal Atrophy market.
· *Multiple Sclerosis Market Analysis *
DelveInsight's Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
· *Septic Shock Market Analysis *
DelveInsight's Septic Shock Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
· *Geographic Atrophy Market Analysis *
DelveInsight's Geographic Atrophy (GA) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
*About **DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
CONTACT: Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com